Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease

Table 1 Patient characteristics

	No A1ATD (n = 628)		A1ATD (n = 47)
Factor	n	Summary	n	Summary	P-value
Female	628	194 (30.9)	47	13 (27.7)	0.64c
Age at cirrhosis diagnosis	628	54.6 ± 9.5	47	55.2 ± 10.3	0.68a
Race	615		47		0.14c
Caucasian		513 (83.4)		45 (95.7)
African-American		65 (10.6)		1 (2.1)
Hispanic		19 (3.1)		1 (2.1)
Other		18 (2.9)		0 (0.0)
HCC	628	195 (31.1)	47	4 (8.5)	0.001c
Follow-up (yr, median)	628	3.2 (1.00, 5.1)	47	4.2 (1.9, 5.2)	0.090b

Values presented as mean ± SD, median (P25, P75), or n (column%). P-values:

^aANOVA,

^bKruskal-Wallis test,

^cPearson’s χ² test. A1ATD: Alpha-1 antitrypsin deficiency; HCC: Hepatocellular carcinoma.